International conference on harmonization (ICH) suggested that bridging study is important to extrapolate clinical results. and also us food and drug administration requires Substantial evidences regarding safety. The review explains about different approaches th at are necessary for obtaining clinical results, various clinical results were performed between similar patient population within same or differe nt regions. moreover no criteria on the evaluation of similarity of clinical results between regions is given .It is important in regulatory submission of new drug application .Mainly this review explains about how clinical results are reproducible.
INTRODUCTION:
US food and drug administration (USFDA) requires well controlled clinical trials for providing substantial evidences and also regarding the safety under investigation. The main purpose of requiring these two clinical trials is to assure the reproducibility and also to provide information regard in generalizability . It can be defined as extension of research finding and conclusions.
The clinical trials can be performed to other similar patient population with in same region or from region to region, which means drugs to be approved by same region or from different regions etc.
ICH
international conference on Harmonisation recommends bridging studies to generate limited amount of clinical data in new region mainly to extrapolate clinical data between two regions. For assurance of generalizability, it is very essential and necessary to determine whether a clinical data providing positive results along with substantial evidence.
This review also introduces concepts of generalizability of positive clinical trials is also introduced. In these review several methods were discussed for evaluation of generalizability which includes Frequentist approach and Bayesian approach[1] .
GENERALIZABILITY:
Clinical trails were to be performed for considering the situation, but due to differences in ethnic factors second clinical and first clinical results were slightly different.
Mainly it includes the differences in mean and variance. Sometimes both mean variance of primary endpoints too. Suppose in first clinical trial if we take old parents and in second clinical trail if we choose adults then the two results will be different.
Suppose both 1 and 2 clinical trails of same population then reproducibility will be different. So for this the scientist named SHAO and CHOW defined about reproducibility and pprobability [3] .To access the same clinical results we have to use the first clinical data to second one so that the results may be same and common.
FREQUENTIST APPROACH:[2]
In two parallel group design, may µ1 µ2 be population mean difference and σ2 be common population variance of first trail In case if the second trail population, mean difference can change to µ1-µ2 +e and population variance changes to c 2 σ2.
In that c>0 [µ1 -µ2] \σ is signal to noise ratio.
Then the signal to noise ratio for population difference in second trial is It is a measure of change in signal to noise ratio for population different patients are randomly assigned for treatment group then the power for second trail is :
1-Tn-2 (t0.975; n-2| ∆Ɵ)+ Tn-2) (t0.975;n-2| ∆Ɵ)
Tn-2 (∆Ɵ) is non central t-distribution with no degrees of freedom and non centrality parameter ∆Ɵ.
In these x1s and s 2 2.s are sample means variance of first trial data base reproducibility, probability in clinical research can be obtained with T and replaced by ∆t.
∆x =1-Tn-2 ( t0.975,n-2| ∆T) + Tn-2 ( t0.975 n-2| ∆t) Ggeneralizability, probability, based on approach as outlined in entry Rreproducibility, probability in clinical research is given by ∆x =1-Tn-2 (t0.975,n-2) ∆Ɵ Values of p∆ can be obtained using 2 and 3 tablets in entry of reproducibility and probability in clinical research.
BAYESIAN APPROACH: [3]
Based on approach given by Π(δ/ γ 2 ,x ) π (γ 2 |x) ɸ =density function of normal distribution T is given by π (γ2\x )=f (u) We may consider avg p∆= ʃ p∆π (∆)d∆.
APPLICATIONS:
Information about bridging studies can be found in ICH GUIDELINES in detail. It is useful in regulatory submission for supplement new drug application mmainly in clinical development after the investigation drug product has been shown to be effective and safe with respect to patient populationn.It is often of interest to study how likely the clinical result is reproducible in similar but slightly different in patient population.
